Shuttle Pharmaceuticals (SHPH) Competitors $0.18 -0.01 (-5.43%) Closing price 03:58 PM EasternExtended Trading$0.18 +0.00 (+1.14%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SHPH vs. SNOA, ENSC, APM, CNSP, EVOK, TCRT, DRMA, JAGX, ONCO, and LIXTShould you be buying Shuttle Pharmaceuticals stock or one of its competitors? The main competitors of Shuttle Pharmaceuticals include Sonoma Pharmaceuticals (SNOA), Ensysce Biosciences (ENSC), Aptorum Group (APM), CNS Pharmaceuticals (CNSP), Evoke Pharma (EVOK), Alaunos Therapeutics (TCRT), Dermata Therapeutics (DRMA), Jaguar Health (JAGX), Onconetix (ONCO), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry. Shuttle Pharmaceuticals vs. Sonoma Pharmaceuticals Ensysce Biosciences Aptorum Group CNS Pharmaceuticals Evoke Pharma Alaunos Therapeutics Dermata Therapeutics Jaguar Health Onconetix Lixte Biotechnology Sonoma Pharmaceuticals (NASDAQ:SNOA) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Which has more risk and volatility, SNOA or SHPH? Sonoma Pharmaceuticals has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -0.93, indicating that its stock price is 193% less volatile than the S&P 500. Does the media prefer SNOA or SHPH? In the previous week, Shuttle Pharmaceuticals had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 2 mentions for Shuttle Pharmaceuticals and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.75 beat Shuttle Pharmaceuticals' score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonoma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shuttle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in SNOA or SHPH? Sonoma Pharmaceuticals received 216 more outperform votes than Shuttle Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformSonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Shuttle PharmaceuticalsN/AN/A Do insiders and institutionals hold more shares of SNOA or SHPH? 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is SNOA or SHPH more profitable? Shuttle Pharmaceuticals has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Sonoma Pharmaceuticals' return on equity of -68.98% beat Shuttle Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-26.82% -68.98% -26.39% Shuttle Pharmaceuticals N/A -583.02%-258.92% Which has preferable earnings & valuation, SNOA or SHPH? Sonoma Pharmaceuticals has higher revenue and earnings than Shuttle Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$13.97M0.37-$4.84M-$4.02-0.79Shuttle PharmaceuticalsN/AN/A-$6.59M-$4.15-0.04 SummarySonoma Pharmaceuticals beats Shuttle Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Shuttle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SHPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SHPH vs. The Competition Export to ExcelMetricShuttle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.10M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.049.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book0.096.406.744.50Net Income-$6.59M$143.98M$3.23B$248.32M7 Day Performance-21.24%1.90%1.49%-0.03%1 Month Performance-30.31%4.01%11.47%12.72%1 Year PerformanceN/A-3.00%16.57%7.38% Shuttle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SHPHShuttle Pharmaceuticals0.8375 of 5 stars$0.18-5.4%N/AN/A$1.10MN/A-0.045SNOASonoma Pharmaceuticals0.2323 of 5 stars$3.13-1.3%N/A+1,533.2%$5.06M$13.97M-0.78180ENSCEnsysce Biosciences0.2418 of 5 stars$2.08-5.0%N/A-78.1%$4.93M$2.23M-0.0810Gap UpAPMAptorum Group0.3515 of 5 stars$0.90-3.0%N/A-76.6%$4.82M$430,000.000.0030Positive NewsGap DownCNSPCNS Pharmaceuticals1.3109 of 5 stars$1.62+34.1%$25.00+1,440.5%-99.8%$4.78MN/A-0.025Earnings ReportHigh Trading VolumeEVOKEvoke Pharma0.1104 of 5 stars$3.19+0.9%N/A-36.3%$4.76M$10.25M-0.294Negative NewsGap UpTCRTAlaunos Therapeutics1.1132 of 5 stars$2.89+1.4%N/A-76.3%$4.74M$10,000.000.0040Positive NewsEarnings ReportGap DownDRMADermata Therapeutics1.3163 of 5 stars$0.78-1.6%$6.00+667.7%-77.5%$4.72MN/A-0.058Positive NewsAnalyst ForecastGap DownJAGXJaguar Health1.608 of 5 stars$6.99-10.0%N/A-98.0%$4.71M$11.69M0.0050Earnings ReportAnalyst ForecastONCOOnconetix0.0635 of 5 stars$0.07+3.7%N/A-98.4%$4.69M$1.87M0.0012News CoverageGap DownLIXTLixte Biotechnology0.3311 of 5 stars$1.41+10.2%N/A-47.2%$4.44MN/A-0.824Positive News Related Companies and Tools Related Companies SNOA Alternatives ENSC Alternatives APM Alternatives CNSP Alternatives EVOK Alternatives TCRT Alternatives DRMA Alternatives JAGX Alternatives ONCO Alternatives LIXT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SHPH) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shuttle Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shuttle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
